**INTRODUCTION**

Rucaparib (N=26) vs Chemotherapy (N=58)

- **17 (60.7%)**
- **1 (2.0%)**

Across all platinum status subgroups, patients had longer median treatment duration with rucaparib vs chemotherapy (N=26) vs Chemotherapy (N=58).

**METHODS**

- Eighty-four patients were randomized to receive either rucaparib (N=49) or platinum-doublet chemotherapy (N=35) following progression on previous platinum-based chemotherapy (Figure 2). Following disease progression on previous platinum-based chemotherapy, patients were randomized to receive either rucaparib (N=49) or platinum-doublet chemotherapy (N=35). The efficacy population consisted of all randomized patients who received at least one dose of assigned treatment. Safety population consisted of all patients with measurable disease at baseline and/or evaluable by CA-125.

**RESULTS**

- **Confirmed response rates in the platinum status subgroup are shown in Table 2.**
- **Rucaparib-treated patients had a larger median duration of response compared to chemotherapy-treated patients:** 5.5 vs 4.4 months in the platinum-resistant subgroup, 7.6 vs 4.6 months in the partially platinum-sensitive subgroup, and 6.4 vs 2.9 months in the fully platinum-sensitive subgroup.
- **Patients with measurable disease at baseline and/or evaluable by CA-125 were randomized to receive either rucaparib (N=49) or platinum-doublet chemotherapy (N=35).**

**Efficacy**

- **PFS**
- **ORR**
- **OS**
- **Grade ≥3**

**Supplementary Material**

- Additional information available in supplementary materials.

**ACKNOWLEDGMENTS**

- Thank you to the patients and physicians who contributed to this study.

**REFERENCE**